UK Regulator Awards Innovation Passports to Three Promising Therapies

The UK's MHRA has granted Innovation Passports to three investigational medicines targeting lung cancer, Huntington's disease, and Alzheimer's disease. These treatments address significant unmet medical needs. The passports provide coordinated support through the UK's Innovative Licensing and Access Pathway (ILAP), aiming to accelerate their development and patient access.